Michael Goldberg, Surge Therapeutics founder and CEO
July 19, 2023 08:00 AM EDT
Financing

Im­munother­a­py dur­ing surgery? Surge Ther­a­peu­tics nabs $32M to ex­pand clin­i­cal plans af­ter first dos­ing

Amber Tong

Weeks ago, Surge Ther­a­peu­tics marked what CEO Michael Gold­berg hopes will go down in his­to­ry as a turn­ing point in can­cer care: the first time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times